Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice.

Abstract

BACKGROUND:

This prospective study collected quality of life (QoL) and pain data during cabazitaxel treatment in patients with advanced metastatic or castration-resistant prostate cancer (mCRPC).

PATIENTS AND METHODS:

Functional Assessment of Cancer Therapy-Prostate (QoL) and Brief Pain Inventory-Short Form (pain) questionnaires were collected over 6 months.

RESULTS:

In 61 patients with mCRPC (median age, 72 years) from 22 centers, metastatic sites were bones (97%), lymph nodes (36%), and visceral (20%); 25% received cabazitaxel in the second line, 29% in the third line, and 46% in the fourth line or beyond. All had been previously treated with docetaxel, except one with paclitaxel, and 75% also with abiraterone, enzalutamide, or both. The median cabazitaxel duration was 3.4 months. Forty-nine patients were evaluable for QoL and 44 for pain. QoL was improved in 37%, maintained in 35%, and deteriorated in 37%. In 27%, pain decreased ≥ 1 level and remained stable in 52%. A total of 34% lowered analgesic drug level. Prostate-specific antigen response ≥ 50% was observed in 11 (32.6%) patients, of whom 7 improved QoL and 1 was stable. At 6 months, 83.6% survived (95% confidence interval, 71.7%-90.8%). A total of 46% had ≥ 1 grade ≥ 3 adverse events, mainly anemia and neutropenia.

CONCLUSION:

Although cabazitaxel was given as the third line and beyond for three-quarters of patients, over one-third had improved QoL and/or decreased pain during treatment.

• Authors: Florence Joly, Stéphane Oudard, Karim Fizazi, Florence Tubach, Jérémy Jove, Clémentine Lacueille, Stéphanie Lamarque, Estelle Guiard, Aurélie Balestra, Cécile Droz-Perroteau, Annie Fourrier-Reglat, Magali Rouyer, Nicholas Moore
• Journal: Clinical genitourinary cancer (Clin Genitourin Cancer) Vol. 18 Issue 5 Pg. e510-e516 (10 2020) ISSN: 1938-0682 [Electronic] United States
• PMID: 32229267 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Chemical References

• Taxoids
• cabazitaxel

Topics

• Aged
• Humans
• Male
• Pain (drug therapy, etiology)
• Prospective Studies
• Prostatic Neoplasms, Castration-Resistant (drug therapy)
• Quality of Life
• Taxoids